Editor at large of the Medical Technology Stock Letter since the mid-1980s, James McCamant uses his experience to provide a broad and deep overview of this exciting juncture of science and commerce. He focuses on why he thinks, from an investor's perspective, that now is such a propitious time to get into the market. Chapters cover a history of the field, how to invest, a state-of-the-art summary of biotechnology, patents and the clinical review process, and the future of biotechnology. Pharmaceutical companies, as opposed to strictly research companies, are particularly well situated to benefit from biotech advances, as they have both the research infrastructure and the capital to last through the long and expensive process of clinical studies. McCamant also includes a chapter on his investment philosophy that is succinct, logical, and itself worth the price of the book.

In Biotech Investing, Jim McCamant offers proven strategies and savvy advice on how to capitalize on the unprecedented opportunities in this high-potential sector. Written by a recognized authority, this book dissects biotech business models from start-up to IPO and discusses in detail the most important factors that affect biotech research. Comprehensive in scope, it looks at the best and worst biotech contenders, discusses all the most newsworthy developments in the field, and shows how they translate into business success or failure. It outlines simple criteria for choosing the best biotech stocks and for understanding the sometimes complicated dynamics of this sector.